SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-092661
Filing Date
2023-12-04
Accepted
2023-12-04 16:01:11
Documents
13
Period of Report
2023-11-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea189451-8k_elevailabs.htm   iXBRL 8-K 35502
2 PRESS RELEASE OF THE COMPANY DATED AS OF NOVEMBER 29, 2023 ea189451ex99-1_elevailabs.htm EX-99.1 9869
  Complete submission text file 0001213900-23-092661.txt   226834

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE elab-20231128_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE elab-20231128_pre.xml EX-101.PRE 22369
5 XBRL SCHEMA FILE elab-20231128.xsd EX-101.SCH 3030
7 EXTRACTED XBRL INSTANCE DOCUMENT ea189451-8k_elevailabs_htm.xml XML 3412
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 231462927
SIC: 2834 Pharmaceutical Preparations